ECSP17043648A - Compuestos co-agonistas de gip y glp-1 - Google Patents
Compuestos co-agonistas de gip y glp-1Info
- Publication number
- ECSP17043648A ECSP17043648A ECIEPI201743648A ECPI201743648A ECSP17043648A EC SP17043648 A ECSP17043648 A EC SP17043648A EC IEPI201743648 A ECIEPI201743648 A EC IEPI201743648A EC PI201743648 A ECPI201743648 A EC PI201743648A EC SP17043648 A ECSP17043648 A EC SP17043648A
- Authority
- EC
- Ecuador
- Prior art keywords
- gip
- glp
- agonist compounds
- peptide
- glucagon
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere a compuestos miméticos del péptido de incretina dual que agoniza los receptores para tanto el polipéptido insulinotrópico dependiente de la glucosa humana (GIP) y péptido-1 similar al glucagón (GLP-1), y pueden ser útiles para tratar diabetes mellitus tipo 2 (T2D).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101488P | 2015-01-09 | 2015-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17043648A true ECSP17043648A (es) | 2017-11-30 |
Family
ID=55315708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201743648A ECSP17043648A (es) | 2015-01-09 | 2017-07-07 | Compuestos co-agonistas de gip y glp-1 |
Country Status (45)
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102455171B1 (ko) | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| EP3551202B1 (en) | 2016-12-06 | 2024-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| WO2018213151A1 (en) * | 2017-05-18 | 2018-11-22 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation comprising incretin-insulin conjugates |
| CN118903385A (zh) | 2017-08-24 | 2024-11-08 | 诺和诺德股份有限公司 | Glp-1组合物及其用途 |
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| WO2019140030A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| AU2019238090B2 (en) | 2018-03-22 | 2024-08-01 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| JP6818940B2 (ja) * | 2018-05-04 | 2021-01-27 | ノヴォ ノルディスク アー／エス | Ｇｉｐ誘導体およびその使用 |
| TWI705820B (zh) * | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| BR112020026671A2 (pt) * | 2018-07-23 | 2021-04-06 | Eli Lilly And Company | Compostos coagonistas de gip/glp1 |
| CA3107344A1 (en) * | 2018-07-23 | 2020-01-30 | Eli Lilly And Company | Methods of using a gip/glp1 co-agonist for therapy |
| FI3826662T3 (fi) * | 2018-07-23 | 2024-11-20 | Lilly Co Eli | Menetelmä gip/glp1-koagonistin käyttämiseksi diabetekseen |
| JP6564539B1 (ja) | 2018-09-14 | 2019-08-21 | 長瀬産業株式会社 | スルホン酸化合物によるペプチド精製方法 |
| WO2020067575A1 (en) | 2018-09-24 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Gip receptor agonist peptide compounds and uses thereof |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| TWI799680B (zh) * | 2019-01-29 | 2023-04-21 | 美商美國禮來大藥廠 | 製備gip/glp1雙重促效劑之方法 |
| AU2020291012A1 (en) | 2019-06-12 | 2021-12-16 | AskGene Pharma, Inc. | Novel IL-15 prodrugs and methods of use thereof |
| AR119471A1 (es) | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| KR20220035199A (ko) | 2019-08-19 | 2022-03-21 | 일라이 릴리 앤드 캄파니 | 인크레틴 유사체의 제조 방법 |
| CN114786706A (zh) | 2019-10-04 | 2022-07-22 | 韩美药品株式会社 | 胰高血糖素、包含glp-1受体和gip受体双重激动剂的组合物、及其治疗用途 |
| CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| AR120714A1 (es) * | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
| TWI770781B (zh) * | 2020-01-23 | 2022-07-11 | 美商美國禮來大藥廠 | Gip/glp1共促效劑化合物 |
| TW202228762A (zh) * | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
| CN111253475B (zh) * | 2020-02-18 | 2021-03-09 | 江苏诺泰澳赛诺生物制药股份有限公司 | Glp-1激动多肽化合物及其盐与合成方法及用途 |
| CA3174635A1 (en) | 2020-03-06 | 2021-09-10 | Sanofi | Peptides as selective gip receptor agonists |
| CN113493503B (zh) * | 2020-04-08 | 2022-08-05 | 浙江道尔生物科技有限公司 | 一种肠促胰岛素类似物及其制备方法和用途 |
| TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| AU2021304762B2 (en) * | 2020-07-06 | 2024-05-02 | Vitalixir (Beijing) Co., Ltd | Novel polypeptide and therapeutic use thereof |
| JP7581385B2 (ja) | 2020-07-22 | 2024-11-12 | ノヴォ ノルディスク アー／エス | 経口送達に好適なｇｌｐ－１受容体およびｇｉｐ受容体共作動薬 |
| TW202214679A (zh) | 2020-07-22 | 2022-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及gip受體共促效劑 |
| JP2023545684A (ja) * | 2020-09-30 | 2023-10-31 | ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド | ポリペプチドコンジュゲートおよび使用の方法 |
| IL301109A (en) | 2020-10-17 | 2023-05-01 | Sun Pharmaceutical Ind Ltd | Glp-1/gip dual agonists |
| CN116615222A (zh) * | 2020-12-02 | 2023-08-18 | 东宝紫星(杭州)生物医药有限公司 | 含内酰胺修饰的多肽类化合物 |
| EP4281464A4 (en) * | 2021-01-20 | 2025-01-01 | Viking Therapeutics Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS |
| EP4294423A1 (en) * | 2021-02-17 | 2023-12-27 | Eli Lilly and Company | Gip/glp1 dual agonist therapeutic methods |
| EP4294419A2 (en) | 2021-02-17 | 2023-12-27 | Eli Lilly And Co. | Tirzepatide therapeutic methods |
| US12215133B2 (en) | 2021-03-25 | 2025-02-04 | Brightgene Bio-Medical Technology Co., Ltd. | GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use |
| CN117222661A (zh) * | 2021-03-25 | 2023-12-12 | 博瑞生物医药（苏州）股份有限公司 | Gip和glp-1的双受体激动剂、药物组合物及用途 |
| CN117642153A (zh) | 2021-05-07 | 2024-03-01 | 伊莱利利公司 | 易蚀片剂 |
| CA3216095A1 (en) * | 2021-05-28 | 2022-12-01 | Zhigan JIANG | Preparation and application of polypeptide |
| WO2022253202A1 (zh) * | 2021-06-01 | 2022-12-08 | 南京知和医药科技有限公司 | 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途 |
| WO2022262825A1 (zh) * | 2021-06-18 | 2022-12-22 | 南京明德新药研发有限公司 | 含内酰胺桥的多肽化合物 |
| US20240360194A1 (en) | 2021-09-06 | 2024-10-31 | Sanofi | New Peptides as Potent and Selective GIP Receptor Agonists |
| US20240239843A1 (en) * | 2021-09-15 | 2024-07-18 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| WO2023089594A1 (en) | 2021-11-22 | 2023-05-25 | Sun Pharmaceutical Industries Limited | Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN118843640A (zh) * | 2022-04-07 | 2024-10-25 | 广东众生睿创生物科技有限公司 | 多肽在制备治疗和/或预防糖尿病及肥胖症及其相关疾病药物中的制药用途 |
| CN116947978A (zh) * | 2022-04-19 | 2023-10-27 | 北京惠之衡生物科技有限公司 | 一种glp-1和gip受体共激动多肽衍生物及其盐和制剂 |
| EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
| KR20250029908A (ko) | 2022-06-30 | 2025-03-05 | 일라이 릴리 앤드 캄파니 | 티르제파티드 조성물 및 용도 |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
| TW202411244A (zh) * | 2022-07-13 | 2024-03-16 | 中國大陸商杭州中美華東製藥有限公司 | Ｇｌｐ－１／ｇｉｐ雙激動劑及其製備方法和用途 |
| WO2024020388A1 (en) * | 2022-07-20 | 2024-01-25 | Viking Therapeutics, Inc. | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders |
| WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
| WO2024059674A1 (en) * | 2022-09-15 | 2024-03-21 | Eli Lilly And Company | Gip and glp-1 dual agonist compounds |
| WO2024061310A1 (zh) * | 2022-09-23 | 2024-03-28 | 博瑞生物医药（苏州）股份有限公司 | 一种glp-1和gip双受体激动剂药物组合物及其用途 |
| WO2024077149A2 (en) | 2022-10-05 | 2024-04-11 | Eli Lilly And Company | Peptides for incretin synthesis |
| WO2024098718A1 (zh) * | 2022-11-07 | 2024-05-16 | 内蒙古博睿精创科技有限公司 | 一种新型长效多肽化合物、组合物及其应用 |
| WO2024112617A2 (en) | 2022-11-21 | 2024-05-30 | Eli Lilly And Company | Process for preparing a gip/glp1 dual agonist |
| WO2024145638A2 (en) | 2022-12-29 | 2024-07-04 | Eli Lilly And Company | Processes and intermediates for preparing tirzepatide |
| WO2024141760A1 (en) | 2022-12-30 | 2024-07-04 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
| US20240270821A1 (en) | 2023-01-31 | 2024-08-15 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| TW202444420A (zh) * | 2023-03-15 | 2024-11-16 | 美商維京治療公司 | 用於治療代謝及肝臟病症之醫藥組合物及方法 |
| CN118684758A (zh) * | 2023-03-23 | 2024-09-24 | 上海民为生物技术有限公司 | 肠促胰岛素类似物及其应用 |
| WO2024206552A1 (en) | 2023-03-31 | 2024-10-03 | Eli Lilly And Company | Tirzepatide for use in treating t2d |
| WO2024213022A1 (zh) * | 2023-04-11 | 2024-10-17 | 上海多米瑞生物技术有限公司 | 肠促胰素类似物及其制备方法和应用 |
| WO2024243243A1 (en) * | 2023-05-21 | 2024-11-28 | Carmot Therapeutics Inc. | Treatment of adults with overweight or obesity with or without weight-related comorbidities |
| CN116832141B (zh) * | 2023-06-06 | 2024-02-09 | 诺博泰科(成都)生物科技有限公司 | 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物 |
| WO2024252367A2 (en) | 2023-06-09 | 2024-12-12 | Sun Pharmaceutical Industries Limited | Novel glp-1/gip dual and glp-1/gcg dual receptor agonists |
| JP2024180368A (ja) | 2023-06-15 | 2024-12-26 | ノヴォ ノルディスク アー／エス | シクロデキストリンを含む医薬製剤 |
| WO2025003471A1 (en) | 2023-06-30 | 2025-01-02 | Zealand Pharma A/S | Combination therapy |
| CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050272652A1 (en) * | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| US20080171695A1 (en) | 2005-02-02 | 2008-07-17 | Novo Nordisk A/S | Insulin Derivatives |
| US20100317057A1 (en) * | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| US9072703B2 (en) * | 2008-08-07 | 2015-07-07 | Ipsen Pharma S.A.S. | Glucose-dependent insulinotropic polypeptide analogues |
| CN106317164A (zh) | 2008-09-12 | 2017-01-11 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| CN101367873B (zh) * | 2008-10-08 | 2011-05-04 | 南开大学 | 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用 |
| KR20110110174A (ko) | 2008-12-19 | 2011-10-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭 |
| GB0917072D0 (en) * | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| JP2013518115A (ja) | 2010-01-27 | 2013-05-20 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物 |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| KR101091041B1 (ko) * | 2010-07-29 | 2011-12-09 | 고려대학교 산학협력단 | 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(ｒｃＧＩＰ) 작용제 및 그 용도 |
| KR20130132931A (ko) | 2010-12-22 | 2013-12-05 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체 활성을 나타내는 글루카곤 유사체들 |
| BR112013015861A2 (pt) * | 2010-12-22 | 2018-06-05 | Marcadia Biotech Inc | métodos para reduzir ganho de peso ou induzir perda de peso, e para tratar hiperglicemia, reduzir níveis de glicose no sangue, ou normalizar níveis de glicose no sangue. |
| DK2694095T3 (en) | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
| KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
| EP2720711A1 (en) | 2011-06-15 | 2014-04-23 | Novo Nordisk A/S | Multi substituted insulins |
| IN2014CN02448A (es) | 2011-09-23 | 2015-06-19 | Novo Nordisk As | |
| WO2013092703A2 (en) * | 2011-12-23 | 2013-06-27 | Zealand Pharma A/S | Glucagon analogues |
| WO2013164483A1 (en) * | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| TWI599575B (zh) | 2012-06-21 | 2017-09-21 | 印第安納大學科技研究公司 | 表現ｇｉｐ受體活性之胰高血糖素類似物 |
| JP2015536314A (ja) | 2012-10-17 | 2015-12-21 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 成長ホルモン送達のための脂肪酸アシル化アミノ酸 |
| EA031428B1 (ru) | 2012-12-21 | 2018-12-28 | Санофи | Функционализированные производные эксендина-4 |
| CA2908581C (en) | 2013-05-28 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Peptide compound |
-
2015
- 2015-01-09 JO JOP/2020/0119A patent/JOP20200119A1/ar unknown
- 2015-12-22 TW TW104143220A patent/TWI582109B/zh active
- 2015-12-22 AR ARP150104252A patent/AR103242A1/es unknown
- 2015-12-22 JO JOP/2015/0334A patent/JO3575B1/ar active
-
2016
- 2016-01-05 NZ NZ732000A patent/NZ732000A/en unknown
- 2016-01-05 CN CN202011598548.2A patent/CN112608377B/zh active Active
- 2016-01-05 HU HUE16703620A patent/HUE045860T2/hu unknown
- 2016-01-05 MD MDE20170269 patent/MD3242887T2/ro unknown
- 2016-01-05 CA CA2973352A patent/CA2973352C/en active Active
- 2016-01-05 EP EP16703620.1A patent/EP3242887B1/en active Active
- 2016-01-05 CR CR20170310A patent/CR20170310A/es unknown
- 2016-01-05 NZ NZ771547A patent/NZ771547A/en unknown
- 2016-01-05 AU AU2016205435A patent/AU2016205435B2/en active Active
- 2016-01-05 RS RS20191110A patent/RS59146B1/sr unknown
- 2016-01-05 TN TN2017000198A patent/TN2017000198A1/en unknown
- 2016-01-05 EP EP19188718.1A patent/EP3597662A1/en active Pending
- 2016-01-05 CN CN201680005007.XA patent/CN107207576B/zh active Active
- 2016-01-05 EA EA202090392A patent/EA202090392A3/ru unknown
- 2016-01-05 NZ NZ755618A patent/NZ755618A/en unknown
- 2016-01-05 ME MEP-2019-238A patent/ME03494B/me unknown
- 2016-01-05 PL PL16703620T patent/PL3242887T3/pl unknown
- 2016-01-05 KR KR1020237004037A patent/KR20230023822A/ko not_active Ceased
- 2016-01-05 LT LT16703620T patent/LT3242887T/lt unknown
- 2016-01-05 MX MX2017008927A patent/MX2017008927A/es unknown
- 2016-01-05 JP JP2016549352A patent/JP6219534B2/ja active Active
- 2016-01-05 MA MA41315A patent/MA41315B1/fr unknown
- 2016-01-05 KR KR1020197006498A patent/KR102330764B1/ko active Active
- 2016-01-05 SG SG11201705603YA patent/SG11201705603YA/en unknown
- 2016-01-05 EA EA201892057A patent/EA035055B1/ru unknown
- 2016-01-05 DK DK16703620.1T patent/DK3242887T3/da active
- 2016-01-05 PE PE2017001142A patent/PE20170954A1/es unknown
- 2016-01-05 PT PT167036201T patent/PT3242887T/pt unknown
- 2016-01-05 NZ NZ771043A patent/NZ771043A/en unknown
- 2016-01-05 SI SI201630358T patent/SI3242887T1/sl unknown
- 2016-01-05 KR KR1020247028815A patent/KR20240135032A/ko active Pending
- 2016-01-05 MY MYPI2017702464A patent/MY193616A/en unknown
- 2016-01-05 PH PH1/2017/501252A patent/PH12017501252B1/en unknown
- 2016-01-05 MA MA050422A patent/MA50422A/fr unknown
- 2016-01-05 EA EA201791281A patent/EA031591B1/ru unknown
- 2016-01-05 KR KR1020217037823A patent/KR20210145311A/ko not_active Ceased
- 2016-01-05 ES ES16703620T patent/ES2747928T3/es active Active
- 2016-01-05 US US14/987,791 patent/US9474780B2/en active Active
- 2016-01-05 KR KR1020177018584A patent/KR101957620B1/ko active Active
- 2016-01-05 WO PCT/US2016/012124 patent/WO2016111971A1/en active Application Filing
- 2016-05-01 UA UAA201707109A patent/UA118239C2/uk unknown
-
2017
- 2017-05-24 IL IL252499A patent/IL252499B/en active IP Right Grant
- 2017-06-01 SV SV2017005453A patent/SV2017005453A/es unknown
- 2017-06-08 ZA ZA2017/03930A patent/ZA201703930B/en unknown
- 2017-06-22 DO DO2017000153A patent/DOP2017000153A/es unknown
- 2017-07-03 CL CL2017001760A patent/CL2017001760A1/es unknown
- 2017-07-05 CO CONC2017/0006737A patent/CO2017006737A2/es unknown
- 2017-07-05 MX MX2021005835A patent/MX2021005835A/es unknown
- 2017-07-07 EC ECIEPI201743648A patent/ECSP17043648A/es unknown
- 2017-09-27 JP JP2017186721A patent/JP6545766B2/ja active Active
-
2019
- 2019-06-19 JP JP2019113638A patent/JP6754867B2/ja active Active
- 2019-09-05 HR HRP20191614 patent/HRP20191614T1/hr unknown
- 2019-09-12 CY CY20191100957T patent/CY1122028T1/el unknown
-
2020
- 2020-08-04 IL IL276492A patent/IL276492B/en active IP Right Grant
-
2021
- 2021-03-16 IL IL281545A patent/IL281545A/en unknown
-
2023
- 2023-01-31 CY CY2023003C patent/CY2023003I2/el unknown
- 2023-01-31 LT LTPA2023504C patent/LTPA2023504I1/lt unknown
- 2023-01-31 FR FR23C1006C patent/FR23C1006I2/fr active Active
- 2023-01-31 HU HUS2300006C patent/HUS2300006I1/hu unknown
- 2023-02-02 NO NO2023005C patent/NO2023005I1/no unknown
- 2023-02-02 FI FIC20230005C patent/FIC20230005I1/fi unknown
- 2023-02-07 NL NL301217C patent/NL301217I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17043648A (es) | Compuestos co-agonistas de gip y glp-1 | |
| SA518391903B1 (ar) | معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي | |
| CL2019001465A1 (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip. | |
| CL2017003185A1 (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
| CO2019005924A2 (es) | Agonistas duales acilados de glp-1/glp-2 | |
| EA035466B9 (ru) | Соединения и способы на основе двойного агониста гип и гпп-1 | |
| AR099977A1 (es) | Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4 | |
| CO2023001960A2 (es) | Agonistas duales glp-1/gip | |
| AR105284A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
| ECSP22095556A (es) | Agonistas dobles de glp-1/gip de acción prolongada | |
| MX2022007666A (es) | Analogos de incretina y sus usos. | |
| MX2015009433A (es) | Polipeptidos novedosos que tienen actividad liberadora de hormonas de la saciedad. | |
| CO2025001430A2 (es) | Agonista dual de glp-1/gip, método de preparación y uso del mismo | |
| ECSP23019850A (es) | Agonistas duales glp-1/gip | |
| BR112023024968A2 (pt) | Tratamento da obesidade e distúrbios relacionados à obesidade | |
| AR107282A1 (es) | Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip) |